If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
169
results.
Updated on
14/09/2026 [06:47:00]
Results 125 to 150 of 169
Absstract of: US20260256917A1
To provide a surface-modified nanodiamond that enables selective accumulation of a sufficient amount of boron atoms in a cancer tissue or a cancer cell and has high killing and injuring ability against the cancer cell. The surface-modified nanodiamond of the present disclosure contains a nanodiamond particle, and a boron cluster-containing group and a group capable of recognizing a cancer cell as surface modification groups of the nanodiamond particle.
Absstract of: US20260258002A1
0000 Novel ionizable lipids, compositions, and methods of using the novel ionizable lipids and compositions are disclosed. Lipid nanoparticle compositions include a novel ionizable lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Lipid nanoparticle compositions further including biologically active agents such as mRNA or DNA are useful in the delivery of biologically active agents to mammalian cells or organs.
Absstract of: WO2026179540A1
The present invention belongs to the field of biomedical science, and specifically relates to the use of an iron nanoparticle in the preparation of a product for controlling Babesia. The iron nanoparticle is in the form of a polysaccharide-coated superparamagnetic iron oxide injection or other formulated products containing the main active ingredient thereof. The iron nanoparticle is used for administration to a subject in the presence of a magnetic field. It has been demonstrated by experiments of the present invention that the iron nanoparticle has a good control effect on Babesia with a weak reproductive capacity under the action of an external magnetic field.
Absstract of: US20260258177A1
The present invention relates to a process for the synthesis of poly(spermine acrylamide) and/or poly(spermine acrylamide-co-N-alkylacrylamide), the process comprising the following steps: a) reacting a mixture of N-acryloxysuccinimide with N-alkylacrylamide, and b) obtaining poly(N-acryloxysuccinimde) polymers, poly(N-alkylacrylamide) polymers and/or copolymers with varying ratios of N-acryloxysuccinimide and N-alkylacrylamide, and c) treating the obtained polymers and/or copolymers of step b) with at least 0.1 equivalent of tri-boc spermine per N-acryloxysuccinimide-repeating unit and obtaining poly(spermine acrylamide) and/or poly(spermine acrylamide-co-N-alkylacrylamide) polymers.
Absstract of: US20260256704A1
0000 It relates to lipo-polyamino acid conjugates of formula (I), and acceptable salts, stereoisomers and mixtures thereof. It also relates to self-assembled particles comprising these lipo-polyamino acid conjugates and optionally active agents, and to compositions comprising the lipo-polyamino acid conjugates or the self-assembled particles comprising them. It relates as well to the use of the lipo-polyamino acid conjugates, self-assembled particles, or compositions comprising them in medicine, cosmetics and diagnostics, and to the use of the lipo-polyamino acid conjugates of formula (I) as carriers.
0000
Absstract of: US20260256698A1
Provided herein are rehydratable powdered formulations of nanocarriers that can be used to encompass hydrophobic or hydrophilic cargo. The formulations can be used for medicinal, agricultural, and research applications. Methods of making the formulations are also provided.
Absstract of: US20260256706A1
The present invention addresses the problem of providing lipid nanoparticles which function as gene transfer carriers capable of selective transfer to the liver or spleen. Lipid nanoparticles which contain a pH-sensitive cationic lipid represented by formula (I) a represents an integer of 3-5; b represents 0 or 1; R1 and R2 each independently represent a group represented by general formula (A) (R11 and R12 each independently represent a linear or branched C2-15 alkyl group; c represents 0 or 1; v represents an integer of 4-12); and X represents a group represented by general formula (B)(d represents an integer of 0-3; and R3 and R4 each independently represent a C1-4 alkyl group or C2-4 alkenyl group, while R3 and R4 may form a 5- to 7-membered non-aromatic heterocycle) or represents a 5- to 7-membered non-aromatic heterocyclic group. (I) (R1)(R2)C(OH)—(CH2)a-(O—CO)b-X. (A): (R11)(R12)—CH—(CO—O)c-(CH2)v-. (B):—(CH2)d-N(R3)(R4).
Absstract of: WO2025160108A1
This invention describes therapeutic compositions, uses and methods using deciparticles for cancer drug delivery. Deciparticle compositions of this invention can be composed of one or more taxane drug compounds complexed with amphiphilic molecules. The amphiphilic molecules may comprise a polyethylene glycol hydrophilic oligomer and a fatty acid alkanoyl hydrophobic core.
Absstract of: WO2025152910A1
Disclosed is an engineered exosome, comprising (a) an EGF polypeptide, fused to a first anchoring polypeptide, (b) a NGF polypeptide, fused to a second anchoring polypeptide, and (c) a PDGF-BB polypeptide, fused to a third anchoring polypeptide, wherein (a), (b) and (c) are anchored on a membrane of the exosome via the first, second and third anchoring polypeptide, respectively, and wherein the EGF polypeptide, the NGF polypeptide and the PDGF-BB polypeptide are exposed on an outer surface of the membrane of the exosome. Also disclosed are compositions, nucleic acid constructs, and uses of the exosome for wound healing.
Absstract of: US20260256146A1
0000 A cerium oxide nanoparticle is produced by adding an oxidant to a solution comprising a boron compound represented by formula (I) and a cerium (III) ion:
0000
wherein n represents an integer of 0 to 2, R represents any of an alkyl group having 1 to 4 carbon atoms, a phenyl group, and a tolyl group, and R′ represents any of a hydrogen atom, an alkyl group having 1 to 4 carbon atoms, a phenyl group, and a tolyl group, and when a plurality of Rs or of R's are present, the plurality of Rs or of R's are optionally the same or different.
Absstract of: CN115484932A
Provided herein are compositions, methods of making the same, and methods for targeted delivery of therapeutic agents to alter the expression and function of target genes, such as proteins involved in lipid and cholesterol metabolism, such as PCSK9. Also provided herein are compositions and methods for treating conditions associated with coronary artery disease.
Absstract of: WO2026179183A1
A hafnium-based complex protein nanoparticle for radiotherapy sensitization, a preparation method therefor and the use thereof. Hafnium ions in solution are used, which enter a protein cavity and then form a complex (precipitate) with hexametaphosphate ligand ions, i.e., biomineralization occurs (with the preparation being completed at room temperature), thereby obtaining a protein-encapsulated hafnium-based complex nanoparticle. When exposed to X-ray radiation, the nanoparticle can enhance the effect of radiotherapy.
Absstract of: US20260258407A1
0000 Compositions and methods for reducing complement activation by introducing one or more alterations into a complement factor B (CFB) polynucleotide in a cell. In particular embodiments, the invention of the disclosure features a base editor system (e.g., a fusion protein or complex comprising a programmable DNA binding protein, a nucleobase editor, and gRNA) for modifying a CFB polynucleotide, where the modification is associated with reduced expression, and/or reduced activity of the CFB polypeptide encoded by the polynucleotide.
Absstract of: US20260256690A1
Compositions and methods for fetal or in utero delivery of active agents are provided. The compositions are most typically administered intravenously via the vitelline vein, umbilical vein, or directly into the amniotic cavity of a pregnant mother. Fibroblast growth factor is to correct structural defects of neural tissue.
Absstract of: AU2026216842A1
The present disclosure is directed to antibodies binding to Glypican 2 and methods of using such antibodies to treat cancers that express or overexpress the Glypican 2 antigen. ug u g
Absstract of: US20260256776A1
Described is a composition comprising (a) a population of particles of an aripiprazole prodrug having a volume based particle size (Dv50) of less than 1000 nm and (b) at least one surface stabilizer comprising an adsorbed component which is adsorbed on the surface of the aripiprazole prodrug particles and a free component available for solubilisation of the aripiprazole prodrug. The surface stabilizer to prodrug ratio provides the optimal quantity of free surface stabilizer for the purposes of producing a lead-in formulation. Also described are methods of treatment using the aforementioned composition.
Absstract of: US20260258142A1
0000 The presently disclosed subject matter relates to antibodies and antigen-binding fragments that bind specifically to phosphorylated PDGFRA, and methods of treating cancer expressing MAN2A1-FER which ectopically phosphorylates PDGFRA. MAN2A1-FER can be expressed in liver cancer, prostate cancer, brain cancer, glioblastoma multiforme, breast cancer, lung cancer, non-small cell lung cancer, colon cancer, and renal cell carcinoma.
Absstract of: WO2026183193A1
Disclosed are nanoparticles and compositions thereof for delivering active agents to the kidney. The nanoparticles include a dendrimer, a targeting ligand, and one or more active agents. From 5% to less than 90% of the dendrimer's surface groups can be modified with one or more functional groups e.g., acetyl groups. The dendrimer can be a PAMAM dendrimer or a saccharide dendrimer. The targeting ligand, such as folic acid, is conjugated to unmodified surface groups. Active agents, including small molecules (e.g., PPAR-α agonists), peptides, or nucleic acids, are encapsulated or associated with the nanoparticles. The nanoparticles have a neutral or positive zeta potential, ranging from about 0 mV to about 30 mV, and a diameter of ranging from 1 to 30 nm. Also disclosed are methods of administering the nanoparticle compositions for treating kidney diseases in a subject in need thereof.
Absstract of: WO2026181080A1
Metal nanoparticles comprising at least one metal atom and a ligand associated with at least a portion of a surface of the metal atom, and uses thereof, are provided. The ligand is made of a first moiety (denoted as X) that is capable of associating with the surface of the metal atom; and an additional moiety (denoted as Y) which is a redox-reactive moiety and/or a second moiety that is capable of associating with the surface of the metal atoms, and optionally a linking moiety that links the first moiety and the additional moiety. The metal nanoparticles are ultra-small nanoparticles. The metal nanoparticles are usable in, for example, catalyzing redox reactions and as coatings for varying surfaces, and are capable of interacting with a myriad of substances, such as liposomes and oligonucleotides, rendering these nanoparticles usable in varying applications.
Absstract of: WO2026183437A1
Provided herein are pharmaceutical compositions that include (a) a dendrimer nanoparticle, wherein the dendrimer nanoparticle comprises Dexamethasone-21-succinate, and (b) a plurality of retinal cells. Also provided herein are methods for treating a degenerative and hereditary retinopathy that include administering any one of the pharmaceutical compositions described herein to a subject in need thereof.
Absstract of: WO2026183342A1
The present technology relates generally to nanoparticles including bovine serum albumin and a first copper complex including diethyldithiocarbamate and Cu2+, and optionally including a second copper complex including diethyldithiocarbamate and 64Cu2+, and optionally including a third copper complex including diethyldithiocarbamate and 67Cu2+ for treating, imaging, and/or detecting a cancer.
Absstract of: WO2026180744A1
The invention provides a lipid composition or LNP comprising (i) one or more cationic ionizable lipids and, optionally, one or more permanent cationic lipids, (ii) one or more phospholipids, (iii) one or more amphiphilic compounds comprising a hydrophilic polymer chain having one or more hydrophobic groups, (iv) optionally cholesterol or a cholesterol ester, (v) a lipophilic agent other than cholesterol and a cholesterol ester, and (vi) one or more polynucleotide(s).
Absstract of: US20260256942A1
The present disclosure discloses a nanocarrier composition with adjustable structure, preparation method and use thereof. The nanocarrier composition is prepared by adding a regulator to lecithin. By adding different types of regulators, the nanocarrier composition can be converted between a liposome structure or a micelle structure. When applied to medical purposes, under the same nanocarrier composition preparation process, under the same nanocarrier composition manufacturing process, the structure of the nanocarrier composition can be changed by simply changing the type of added regulator, thereby controlling the drug release time, drug penetration and bioavailability. The nanocarrier composition can be converted into a suitable structure to facilitate drug delivery according to the requirements of different dosage forms.
Absstract of: US20260256707A1
Disclosed herein are aspects of a compound according to Formula IAlso disclosed are compositions comprising the compounds that may be useful for delivering agents such as therapeutic and/or prophylactic agents, for example, nucleic acids such as, but not limited to, DNA or RNA, small molecules, proteins, polypeptides or peptides. In some aspects, the composition is a lipid nanoparticle. Also disclosed herein are lipid nanoparticles comprising the compounds and methods for making and using the nanoparticles.
Nº publicación: US20260256943A1 03/09/2026
Applicant:
CORE QUANTUM TECH INC [US]
Core Quantum Technologies, Inc.
Absstract of: US20260256943A1
Generally, a nanomaterial polymer encapsulation system useful in the production of nanocomposites comprising an inorganic nanoparticle encapsulated in a hydrophobic region of a polymer with the external hydrophilic region of the polymer ensuring water-solubility and affording a functional group which can be utilized for the production of nanocomposite conjugates.Specifically, particular embodiments can comprise nanocomposites including one or more inorganic nanoparticles including, metal and non-metal isotopes, a superparamagnetic iron oxide nanoparticle (“SPION”), and/or quantum dots encapsulated in a polystyrene-b-polyethylene glycol affording a functional group that can be activated to conjugate antibodies, modified antibodies, or antibody fragments for the capture of target moieties which in suspension can be nebulized into an inductively coupled plasma time-of-flight mass spectrometry instrument to identify and quantify diverse features of cellular systems.
BOPI
Electronic site
